Not available
Quote | Cutera Inc. (NASDAQ:CUTR)
Last: | $1.66 |
---|---|
Change Percent: | -1.3% |
Open: | $1.56 |
Close: | $1.66 |
High: | $1.6977 |
Low: | $1.5507 |
Volume: | 563,440 |
Last Trade Date Time: | 07/16/2024 03:00:00 am |
News | Cutera Inc. (NASDAQ:CUTR)
2024-06-21 15:00:42 ET More on the markets SPY: The Upside Is Likely Capped SPY: Rating Downgrade Due To Overvaluation Perfect Time For November Election Protection UBS says the current market conditions and the late 1990s have many differences Wolfe ...
2024-06-16 07:05:13 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . Read the full article on Seeking Alpha For further details see: Wall Street Breakfast: The Week Ahead
Message Board Posts | Cutera Inc. (NASDAQ:CUTR)
Subject | By | Source | When |
---|---|---|---|
The gaining | SFGiants | investorshub | 05/10/2023 11:48:00 AM |
$CUTR Price gaining up | Soapy Bubbles | investorshub | 05/10/2023 5:21:31 AM |
$CUTR Have a look at this | Soapy Bubbles | investorshub | 05/08/2023 7:04:25 PM |
$CUTR MomentumIts trading | Penny Roger$ | investorshub | 05/06/2023 5:01:37 AM |
Looks pretty positive | Pro-Life | investorshub | 05/05/2023 11:11:36 AM |
News, Short Squeeze, Breakout and More Instantly...
New insights reveal the profound impact of acne and the growing interest in modern treatments Cutera, Inc. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announces the release of important new acne survey data as part of June’s Acne Awareness Month. Th...
Experienced Healthcare Executive Brings Extensive Financial and Operational Expertise to Cutera Board of Directors CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announced today that Jeryl “Jeri” Hilleman will join its Board of Direct...
CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will hold an investor webinar at 11 a.m. PDT on June 20, 2024, to present an overview of AviClear, the first FDA-cleared energy device for the long-term treatment of mild, moderate, and...